COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,252 Articles (22,733 medRxiv, 8,519 bioRxiv)

Most recent first Previous |  Page 1621: Articles 16201-16210  | Next

The emergence of SARS-CoV-2 variant(s) and its impact on the prevalence of COVID-19 cases in Nabatieh region, Lebanon
Noureddine, F. Y., Chakkour, M., El Roz, A., Reda, J., Al Sahily, R., Assi, A., Joma, M., Salami, H., Hashem, S. J., Harb, B., Salami, A., Ghssein, G.
10.1101/2021.04.08.21255005 — Posted: 2021-04-13
Detection of SARS-CoV-2 variant 501Y.V2 in Comoros Islands in January 2021
Agoti, C. N., Githinji, G., Mohammed, K. S., Lambisia, A. W., de Laurent, Z. R., Mburu, M. W., Ong'era, E. M., Morobe, J. M., Otieno, E., Yahaya, H. A., Abdallah, K. S., Diarra, A., Yahaya, A. A., Athanasius, D. F., Gumede-Moeletsi, N., Tsofa, B., Borus, P., Bejon, P., Nokes, J. D., Ocholla, I. L.
10.1101/2021.04.08.21254321 — Posted: 2021-04-13
A multiplexed high-throughput neutralization assay reveals a lack of activity against multiple variants after SARS-CoV-2 infection
Fenwick, C., Turelli, P., Pellaton, C., Farina, A., Campos, J., Raclot, C., Pojer, F., Cagno, V., Pantaleo, G., Trono, D.
10.1101/2021.04.08.21255150 — Posted: 2021-04-13
Antibody Response after First-dose of ChAdOx1-nCOV (Covishield) and BBV-152 (Covaxin) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study
SINGH, A. K., Phatak, S., Singh, N. K., Gupta, A., Sharma, A., Bhattacharjee, K., SINGH, R.
10.1101/2021.04.07.21255078 — Posted: 2021-04-13 Discussion: Onsite
Elevated anti-SARS-CoV-2 antibodies and IL-6, IL-8, MIP-1β, early predictors of severe COVID-19.
Codina, H., Vieitez, I., Gutierrez-Valencia, A., Skouridou, V., Martínez, C., Patiño, L., Botero-Gallego, M., Trujillo-Rodríguez, M., Serna-Gallego, A., Muñoz-Muela, E., M. Bobillo, M., Pérez, A., Cabrera-Alvar, J. J., Crespo, M., O'Sullivan, C. K., Ruiz-Mateos, E., Poveda, E.
10.1101/2021.04.13.439586 — Posted: 2021-04-13
The effects of quality of evidence communication on perception of public health information about COVID-19: two randomised controlled trials
Schneider, C. R., Freeman, A. L. J., Spiegelhalter, D., van der Linden, S.
10.1101/2021.04.07.21255010 — Posted: 2021-04-13 Discussion: Onsite
From partial to whole genome imputation of SARS-CoV-2 for epidemiological surveillance
Ortuno, F. M., Loucera, C., Casimiro-Soriguer, C. S., Lepe, J. A., Camacho Martinez, P., Merino Diaz, L., Chueca, N., de Salazar, A., Garcia, F., Perez-Florido, J., Dopazo, J.
10.1101/2021.04.13.439668 — Posted: 2021-04-13
Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease
Sugiyama, M., Cui, H., Redka, D. S., Karimzadeh, M., Rujas, E., Maan, H., Hayat, S., Cheung, K., Misra, R., McPhee, J. B., Viirre, R. D., Haller, A., Botelho, R., Karshafian, R., Sabatinos, S. A., Fairn, G. D., Madani Tonekaboni, S. A., Windemuth, A., Julien, J.-P., Shahani, V., MacKinnon, S. S., Wang, B., Antonescu, C. N.
10.1101/2021.04.13.439274 — Posted: 2021-04-13 Discussion: Offsite
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
Wu, K., Choi, A., Koch, M., Elbashir, S., Ma, L., Lee, D., Woods, A., Henry, C., Palandjian, C., Hill, A., Quinones, J., Nunna, N., O'Connell, S., McDermott, A. B., Falcone, S., Narayanan, E., Colpitts, T., Bennett, H., Corbett, K., Seder, R., Graham, B. S., Stewart-Jones, G. B., Carfi, A., Edwards, D. K.
10.1101/2021.04.13.439482 — Posted: 2021-04-13
Epitope classification and RBD binding properties of neutralizing antibodies against SARS-CoV-2 variants of concern
Deshpande, A., Harris, B. D., Martinez-Sobrido, L., Kobie, J. J., Walter, M. R.
10.1101/2021.04.13.439681 — Posted: 2021-04-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).